Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shmuel Yaccoby

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Clinical Lymphoma & Myeloma|October 10, 2006
Response to bortezomib and activation of osteoblasts in multiple myelomaMaurizio Zangari, Shmuel Yaccoby, Federica Cavallo, et al.
Haematologica|June 12, 2025
Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu miceWen Ling, Maurizio Zangari, Frits Van Rhee, et al.
Cancer Biology & Therapy|May 22, 2015
A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatmentDavid Abasiwani Alagpulinsa, Shmuel Yaccoby, Srinivas Ayyadevara, et al.
Molecular Cancer Therapeutics|January 1, 2016
A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP InhibitionDavid A Alagpulinsa, Srinivas Ayyadevara, Shmuel Yaccoby, et al.
British Journal of Haematology|March 4, 2006
Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survivalYun Ge, Fenghuang Zhan, Bart Barlogie, et al.
American Journal of Hematology|November 5, 2008
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivoAngela Pennisi, Xin Li, Wen Ling, et al.
Blood|October 28, 2006
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivoShmuel Yaccoby, Wen Ling, Fenghuang Zhan, et al.
British Journal of Haematology|September 1, 2007
Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell linesXin Li, Angela Pennisi, Fenghuang Zhan, et al.
British Journal of Haematology|February 14, 2002
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activityShmuel Yaccoby, Roger N Pearse, Cherie L Johnson, et al.
Blood|October 24, 2002
Antimyeloma efficacy of thalidomide in the SCID-hu modelShmuel Yaccoby, Cherie L Johnson, Susan C Mahaffey, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Clinical Lymphoma & Myeloma|October 10, 2006
Response to bortezomib and activation of osteoblasts in multiple myelomaMaurizio Zangari, Shmuel Yaccoby, Federica Cavallo, et al.
Haematologica|June 12, 2025
Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu miceWen Ling, Maurizio Zangari, Frits Van Rhee, et al.
Cancer Biology & Therapy|May 22, 2015
A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatmentDavid Abasiwani Alagpulinsa, Shmuel Yaccoby, Srinivas Ayyadevara, et al.
Molecular Cancer Therapeutics|January 1, 2016
A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP InhibitionDavid A Alagpulinsa, Srinivas Ayyadevara, Shmuel Yaccoby, et al.
British Journal of Haematology|March 4, 2006
Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survivalYun Ge, Fenghuang Zhan, Bart Barlogie, et al.
American Journal of Hematology|November 5, 2008
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivoAngela Pennisi, Xin Li, Wen Ling, et al.
Blood|October 28, 2006
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivoShmuel Yaccoby, Wen Ling, Fenghuang Zhan, et al.
British Journal of Haematology|September 1, 2007
Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell linesXin Li, Angela Pennisi, Fenghuang Zhan, et al.
British Journal of Haematology|February 14, 2002
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activityShmuel Yaccoby, Roger N Pearse, Cherie L Johnson, et al.
Blood|October 24, 2002
Antimyeloma efficacy of thalidomide in the SCID-hu modelShmuel Yaccoby, Cherie L Johnson, Susan C Mahaffey, et al.
Pageof 7